Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X9UA
|
|||
| Former ID |
DIB013670
|
|||
| Drug Name |
Vatelizumab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple sclerosis [ICD-11: 8A40; ICD-9: 340] | Phase 2 | [1] | |
| Company |
Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02222948) Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis. U.S. National Institutes of Health. | |||
| REF 2 | Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect. 2015 June; 3(3): e00146. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.